1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Azenta, Inc.

Azenta, Inc.

AZTA
Azenta, Inc.US flagNASDAQ Global Select
36.76
USD
+1.03
- -
1.61BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.41
7.24
8.2
6.34
7.58
8.96
4.64
5.28
6.92
7.42
8.32
12.58
12.98
13.4
Basic EPS, GAAP
-0.03
0.47
0.21
-1.01
0.9
1.65
6.08
0.88
1.49
28.48
-0.22
-3.62
-1.22
-2.69
Free Cash Flow per Basic Share
0.77
0.72
0.41
0.39
1.2
0.87
0.93
-0.03
1.31
-7.26
-0.51
0.27
0.84
0.22
Dividend per Share
0.32
0.34
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.1
- -
- -
- -
- -
Book Value per Share
9.49
9.61
9.35
8.07
8.7
10.15
15.75
16.44
17.83
44.83
43.82
38.79
37.66
34.51
Tangible Book Value per Share
7.12
7.08
6.73
3.93
4.54
5.12
5.52
7.42
9
35.61
25.17
20.88
20.12
20.04
Basic Weighted Avg Shares
66
67
67
69
70
70
72
74
74
75
66
46
46
46
Sales/Revenue/Turnover
422
483
553
434
527
632
334
389
514
555
551
573
594
614
Operating Margin (%)
-2.47
0.74
3.91
-1.58
3.31
5.09
-13.78
-9.25
-5.98
-4.22
-10.28
-6.95
-3.65
-3.79
Depreciation Expense
24
23
25
28
28
37
54
65
65
54
86
91
61
56
Net Income, GAAP
-2
31
14
-69
63
117
437
65
111
2,133
-15
-165
-56
-123
Effective Tax Rate (%)
- -
- -
19.25
- -
23.28
- -
- -
- -
- -
- -
- -
- -
- -
280.73
Profit Margin (%)
-0.52
6.5
2.57
-16.01
11.87
18.46
130.89
16.69
21.56
383.95
-2.65
-28.76
-9.39
-20.04
Working Capital
262
260
243
180
205
399
375
438
432
2,229
1,208
627
471
409
LT Debt
- -
7
- -
- -
- -
194
50
68
95
49
60
57
51
54
Total Equity
633
643
632
554
608
718
1,139
1,214
1,325
3,363
2,534
1,768
1,727
1,510
Return on Invested Capital (%)
- -
- -
2.7
- -
2.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
2.27
- -
10.84
- -
- -
- -
- -
- -
- -
- -
- -
-7.47
Return on Common Equity (%)
-0.35
4.92
2.23
-11.72
10.78
17.59
47.12
5.51
8.72
90.98
-0.5
-7.67
-3.19
-7.72

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
54
56
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
44
Market Capitalization
1,531
974
1,117

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
780
727
681
Cash, Cash Equivalents & STI
410
381
326
Accounts Receivable, Net
142
131
144
Inventories
82
79
79
Total Current Liabilities
267
257
273
Payables & Accruals
99
92
84
ST Debt
- -
- -
- -
Deferred Revenue
70
75
71

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.65%
21.16%
-2.31%
Free Cash Flow
-540.73%
-1,099.22%
210.29%
Net Income, GAAP
225.4%
551.29%
-66.18%
Sales/Revenue/Turnover
3.61%
9.43%
3.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
142
136
144
170
573
2025
147
143
144
159
594
2026
149
145
161
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.28
-2.47
-0.12
-0.11
-3.62
2025
-0.24
-1.04
-1.05
1.11
-1.22
2026
-0.34
-3.49
0.05
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Martin D. Madaus
Full Time Employees
2,900
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
200 Summit Drive Burlington MA United States of America 01803
IPO Date
Feb 2, 1995
CIK
0000933974
Website
azenta.com
Similar Companies
PT Jayamas Medica Industri Tbk (OMED.JK)
MagForce AG (MF6.DE)
Tobii Dynavox AB (publ) (TDVOX.ST)
Austco Healthcare Limited (AHC.AX)
Sartorius Stedim Biotech S.A. (SRTOY)
Becton, Dickinson and Company (0R19.L)
Business
Azenta, Inc. Azenta, Inc. (Nasdaq: AZTA) provides life sciences sample exploration and management solutions to pharmaceutical, biotechnology, academic, and healthcare institutions worldwide. The company offers consumables and instruments including 2D sample storage tubes and bench-top equipment from brands such as FluidX, Ziath, and 4titude; automated stores and cryogenics systems; sample storage and repository services through BioStorage Technologies; GENEWIZ multiomics and synthesis solutions encompassing next-generation sequencing, genomics, and transgene expression cassettes; sample management LIMS software like FreezerPro and Limfinity; cold chain solutions from B Medical Systems including temperature-controlled storage and transportation; and biological sample preparation from Matrical Bioscience. Azenta operates globally across North America, Europe, and Asia from its headquarters in Burlington, Massachusetts, where it was rebranded from Brooks Automation in December 2021 following a corporate restructuring that divested its semiconductor solutions group. Recent developments include a May 2025 strategic partnership with Form Bio to integrate GENEWIZ sequencing with AI-driven AAV gene therapy analysis for improved vector safety and development speed; and a November 2025 collaboration with the PRECEDE Foundation to provide biorepository storage and logistics for pancreatic cancer early detection research.

Company News

Company News APIChatGPT

  • newsfilecorp.com

    ROSEN, LEADING INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • newsfilecorp.com

    ROSEN, NATIONALLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • defenseworld.net

    Azenta (NASDAQ:AZTA) Shares Down 9.3% – Here’s Why

  • newsfilecorp.com

    ROSEN, TOP-RANKED TRIAL ATTORNEYS, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • globenewswire.com

    Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  • defenseworld.net

    Azenta, Inc. (NASDAQ:AZTA) Stock Has Average Target Price of $41.20

  • newsfilecorp.com

    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • newsfilecorp.com

    ROSEN, SKILLED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • newsfilecorp.com

    ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • globenewswire.com

    Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  • gurufocus.com

    Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • prnewswire.com

    Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • newsfilecorp.com

    ROSEN, A LEADING NATIONAL FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • newsfilecorp.com

    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • newsfilecorp.com

    ROSEN, A LEADING LAW FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • gurufocus.com

    Azenta Inc (AZTA) Shares Fall 7.9% -- What GF Score of 83 Tells Investors

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

  • globenewswire.com

    Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  • gurufocus.com

    Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

  • prnewswire.com

    Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA